The roles of integrins in function of human neutrophils after their migration through endothelium into interstitial matrix.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Chemotaxis, Leukocyte*; Integrins/*physiology ; Neutrophils/*physiology; Adult ; Apoptosis ; Endothelium/cytology ; Humans ; Neutrophils/cytology ; Phagocytosis

We investigated the changes in neutrophil phenotype and function after transendothelial migration, and the roles played by integrin receptors in their behaviour. Neutrophils were tracked microscopically as they migrated through endothelial cells into collagen gels, and were retrieved at desired times. When endothelial cells were treated with increasing doses of tumour necrosis factor-α, neutrophils not only migrated in greater number, but also to a greater depth in the gel. Apoptosis was barely detectable in neutrophils retrieved after 24h, and many remained viable and motile at 48h. Neutrophils retrieved after 1h had increased oxidative capacity and at 24h had similar capacity as freshly-isolated neutrophils. However, by then they had impaired ability to phagocytose bacteria. Compared to fresh neutrophils, total mRNA was halved by 24h, but while β2-integrin expression decreased, β1- and β3-integrin increased along with ICAM-1. Studies of integrin blockade indicated that while β2-integrins were needed to cross the endothelial barrier, no integrins were required for migration within the gel. β2-integrins also contributed to phagocytosis, but their binding was not required for prolonged survival. These results demonstrate a model for integrated analysis of neutrophil migration and function, and describe development of effector functions and the roles of integrins in human neutrophils for the first time.

Microvasc Res. 1993 Jan;45(1):33-45. (PMID: 8479340)
Blood. 2013 Mar 7;121(10):1677-89. (PMID: 23305731)
Annu Rev Physiol. 1995;57:827-72. (PMID: 7778885)
Blood. 1997 Jan 1;89(1):166-75. (PMID: 8978289)
Immunity. 1996 Dec;5(6):653-66. (PMID: 8986723)
J Immunol. 1997 Jan 15;158(2):945-53. (PMID: 8993015)
Am J Physiol. 1997 Jan;272(1 Pt 1):C295-309. (PMID: 9038836)
Shock. 1997 Nov;8(5):357-61. (PMID: 9361346)
Kidney Int. 1998 Jan;53(1):84-91. (PMID: 9453003)
J Exp Med. 1998 Jun 15;187(12):2091-6. (PMID: 9625769)
Clin Sci (Lond). 1998 May;94(5):461-71. (PMID: 9682667)
Blood. 1998 Dec 15;92(12):4819-27. (PMID: 9845549)
Microsc Res Tech. 1998 Dec 1;43(5):369-78. (PMID: 9858334)
Cell Adhes Commun. 1998;6(6):491-501. (PMID: 9929742)
J Vasc Res. 1999 Nov-Dec;36(6):477-85. (PMID: 10629423)
Blood. 2000 Mar 1;95(5):1804-9. (PMID: 10688841)
J Immunol. 2000 Jun 1;164(11):5961-9. (PMID: 10820279)
J Immunol. 2001 Mar 1;166(5):3476-83. (PMID: 11207306)
Cell Signal. 2001 May;13(5):335-43. (PMID: 11369515)
Eur J Immunol. 2002 Feb;32(2):486-93. (PMID: 11828365)
J Leukoc Biol. 2002 Oct;72(4):718-26. (PMID: 12377941)
J Exp Med. 2002 Nov 4;196(9):1201-11. (PMID: 12417630)
Nat Rev Immunol. 2002 Dec;2(12):965-75. (PMID: 12461569)
J Vasc Res. 2003 Sep-Oct;40(5):435-41. (PMID: 14530600)
J Vasc Res. 2003 Sep-Oct;40(5):467-79. (PMID: 14566092)
Microbes Infect. 2003 Nov;5(14):1299-306. (PMID: 14613773)
Microbes Infect. 2003 Nov;5(14):1317-27. (PMID: 14613775)
J Clin Invest. 1989 Jun;83(6):2008-17. (PMID: 2566624)
Biophys J. 1992 Feb;61(2):306-15. (PMID: 1547321)
Blood. 1992 Mar 15;79(6):1545-52. (PMID: 1347710)
Blood. 1992 Dec 1;80(11):2920-4. (PMID: 1280481)
J Leukoc Biol. 1999 Mar;65(3):356-63. (PMID: 10080540)
J Exp Med. 1999 Oct 4;190(7):923-34. (PMID: 10510082)
J Immunol. 1999 Nov 1;163(9):5029-38. (PMID: 10528208)
J Leukoc Biol. 2005 Feb;77(2):159-65. (PMID: 15539457)
Blood. 2005 Jul 15;106(2):584-92. (PMID: 15811956)
J Leukoc Biol. 2005 Nov;78(5):1025-42. (PMID: 16204621)
J Leukoc Biol. 2006 Feb;79(2):303-11. (PMID: 16330528)
J Leukoc Biol. 2006 Apr;79(4):779-88. (PMID: 16461737)
J Exp Med. 2006 Jun 12;203(6):1519-32. (PMID: 16754715)
J Leukoc Biol. 2007 Mar;81(3):686-95. (PMID: 17164427)
Nat Rev Immunol. 2007 Sep;7(9):678-89. (PMID: 17717539)
Nature. 2008 May 1;453(7191):51-5. (PMID: 18451854)
J Cell Sci. 2008 Jun 1;121(11):1773-83. (PMID: 18492791)
Cell Immunol. 2008 Jan;251(1):56-61. (PMID: 18479679)
J Leukoc Biol. 2009 Jan;85(1):98-107. (PMID: 18948550)
Eur J Immunol. 2009 Jan;39(1):113-25. (PMID: 19130557)
Clin Exp Immunol. 2009 Mar;155(3):559-66. (PMID: 19077082)
PLoS One. 2009;4(3):e4693. (PMID: 19259262)
Blood. 2010 Jul 29;116(4):625-7. (PMID: 20410504)
Trends Immunol. 2010 Aug;31(8):318-24. (PMID: 20620114)
Thromb Haemost. 2010 Sep;104(3):599-608. (PMID: 20589324)
Exp Cell Res. 2011 Feb 1;317(3):276-92. (PMID: 21056557)
Nat Immunol. 2011 Aug;12(8):761-9. (PMID: 21706006)
J Exp Med. 2012 Jun 4;209(6):1219-34. (PMID: 22615129)
Nat Immunol. 2013 Jan;14(1):41-51. (PMID: 23179077)
Blood. 1993 Aug 15;82(4):1165-74. (PMID: 7688989)

PG/08/128/26525 United Kingdom British Heart Foundation

0 (Integrins)

Date Created: 20150224 Date Completed: 20151203 Latest Revision: 20181113

20231215

PMC4338182

10.1371/journal.pone.0118593

25706870